Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: A systematic review and meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 8, 2014, Pages 1429-1440

  Fu, Qi Han ^a   Zhang, Qi ^a   Bai, Xue Li ^a   Hu, Qi Da ^a   Su, Wei ^a   Chen, Yi Wen ^a   Su, Ri Ga ^a   Liang, Ting Bo ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; Sorafenib; Transarterial embolization

Indexed keywords

ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CAMPTOTHECIN; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LIDOCAINE; LIVER PROTECTIVE AGENT; MITOMYCIN; OXALIPLATIN; PIRARUBICIN; SORAFENIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CHEMOEMBOLIZATION; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; META ANALYSIS; MONOTHERAPY; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904318936     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1684-5     Document Type: Article

References (44)

1. Abou-Alfa GK (2011) TACE and sorafenib: a good marriage? J Clin Oncol Off J Am Soc Clin Oncol 29(30):3949-3952 (Epub 2011/09/14)
2. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 24(26):4293-4300 (Epub 2006/08/16)
3. Biolato M, Marrone G, Racco S, Di Stasi C, Miele L, Gasbarrini G et al (2010) Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 14(4):356-362 (Epub 2010/05/26)
4. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G et al (2011) The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 34(2):205-213 (Epub 2011/05/25)
5. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1):47-54 (Epub 2002/07/02)
6. Chen SM, Wang YS, Xie H (2012) Clinical observation of sorafenib combined with transcatheter arterial chemoembolization for treating senile primary carcinoma of the liver. China J Mod Med 22(25):71-73
7. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012) Management of HCC. J Hepatol 56(Suppl 1):S75-S87 (Epub 2012/02/04)
8. Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z et al (2010) Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15(11):1198-1204 (Epub 2010/11/03)
9. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340(10):745-750 (Epub 1999/03/11)
10. Galle P, Blanc J, Van Laethem JL, Marrero J, Beaugrand M, Moscovici M et al (2008) 994 efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the sharp trial. J Hepatol 48:S372
11. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J et al (2011) Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 81(Suppl 1):158-164 (Epub 2012/01/11)
12. Harada T, Matsuo K, Inoue T, Tamesue S, Nakamura H (1996) Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 224(1):4-9 (Epub 1996/07/01)
13. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I et al (2008) Prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8:349 (Epub 2008/11/28)
14. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13 (Epub 2005/04/21)
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12 (Pubitemid 26120810)
16. Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10(10):967-974 (Epub 2009/09/22)
17. Jiang HY, Xie XD (2010) Sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma. Hainan Med J 21(23):6-9
18. Kim HY, Park JW (2011) Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. Dig Dis 29(3):303-309 (Epub 2011/08/11)
19. Kim YB, Park YN, Park C (2001) Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38(2):160-166 (Epub 2001/02/24)
20. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T et al (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47(14):2117-2127 (Epub 2011/06/15)
21. Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J et al (2010) Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE) [abstract no. TPS178]. J Clin Oncol Off J Am Soc Clin Oncol 26:TPS178
22. Lencioni R, Llovet JM, Han GH, Tak WY, Yang JM, Leberre MA et al (2012) Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 30:154
23. Llovet JM, Schwartz M, Mazzaferro V (2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25(2):181-200 (Epub 2005/05/27)
24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390 (Epub 2008/07/25)
25. Lu L, Wang X, Zhang B, Zhang DH, Gu JY (2012) Effects of sorafenib on recurrent hepatocelluar carcinoma after liver transplantation. Chin J Tissue Eng Res 16(31):5706-5710
26. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liv Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liv 42(Suppl 3):S206-S214 (Epub 2010/06/25)
27. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 29(30):3960-3967 (Epub 2011/09/14)
28. Qi YY, Zou LG, Huang XB, Hu YD, Liu WJ (2010) The MSCT evaluation of TACE plus sorafenib for patients with massive primary hepatocellular carcinoma. Mod Oncol 18(11):2188-2190
29. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ et al (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 12:263
30. Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70(3):585-590 (Epub 1992/08/01)
31. Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9(6):739-745 (Epub 2009/06/06)
32. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F (2012) Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 17(3):359-366 (Epub 2012/02/16)
33. Strebel BM, Dufour JF (2008) Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 8(11):1743-1749 (Epub 2008/11/06)
34. Sun Z, Ming L, Zhu X, Lu J (2002) Prevention and control of hepatitis B in China. J Med Virol 67(3):447-450 (Epub 2002/07/13)
35. Tak WY, Yu S, Tsao CJ, Yang TS, Kim JS, Qin SK et al (2009) Impact of prior TACE/TAE on the efficacy and safety of sorafenib in patients from the Asia-Pacific Region with advanced hepatocellular carcinoma (HCC). J Hepatol 50(S1):S301
36. Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY et al (2010) Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 31(12):1643-1648 (Epub 2010/11/26)
37. Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100(1):1-8 (Epub 2008/11/29)
38. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P et al (2010) Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51:165-173
39. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49(5):523-529 (Epub 2008/06/24)
40. Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y et al (2009) New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan to kagaku ryoho (Cancer Chemother) 36(13):2495-2501 (Epub 2009/12/17)
41. Wei XY, Rao RS (2009) Sorafenib combination with transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. Pract Clin Med 10(11):17-19
42. Widakowich C, de Castro G Jr, de Azambuja E Jr, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12(12):1443-1455 (Epub 2008/01/01)
43. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117-123 (Epub 2008/01/29)
44. Wu XB, Lin DX, Zhou MT, Hu WH, Shi HQ, Zhang QY (2010) Clinical effect of transcatheter arterial chemoembolization combined with sorafenib on advanced hepa-tocellular carcinoma. J Hepatopanereatobiliary Surg 22(6):466-468